GlassScriptPhysician profile
Adolph J Nava
NPI 1518049733
$10,771.42
in general payments reported to CMS, 2019-2025
36 companies · $1,918 in 2025
The $1,918 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,554 · 2020: $807 · 2021: $834 · 2022: $1,117 · 2023: $1,859 · 2024: $2,682 · 2025: $1,918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,458.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,038.23 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,795.75 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,198.11 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $800.09 | 2019-2025 | Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $579.30 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $568.34 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $497.19 | 2022-2025 | |
| Novo Nordisk INC | $471.10 | 2021-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $468.08 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $350.79 | 2019-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $260.64 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $232.11 | 2023-2025 | Arexvy, Shingrix |
| Abbvie INC. | $224.22 | 2021-2023 | |
| Pfizer INC. | $196.44 | 2019-2024 | |
| Daiichi Sankyo INC. | $135.78 | 2024 | Injectafer |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $134.16 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Medline Industries LP | $104.98 | 2019 | |
| Angiodynamics, INC. | $97.98 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $87.86 | 2023-2024 | Inpefa |
| Mylan Specialty L.P. | $67.26 | 2024 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $63.20 | 2019 | |
| Abbott Laboratories | $52.54 | 2023-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $49.84 | 2021-2024 | Dexcom G6 Transmitter |
| Viatris Specialty LLC | $48.62 | 2025 | Yupelri |
| Medtronic, INC. | $28.84 | 2023 | Kyphon Express II Kyphopak Tray |
| Nabriva Therapeutics, Plc | $28.68 | 2022 | |
| Chiesi USA, INC. | $27.49 | 2025 | Elfabrio |
| Biohaven Pharmaceuticals, INC. | $21.51 | 2021 | |
| Kyowa Kirin, INC. | $21.13 | 2025 | |
| Horizon Therapeutics Plc | $20.66 | 2021 | |
| Azurity Pharmaceuticals, INC. | $19.98 | 2024 | |
| Seqirus USA INC | $19.74 | 2025 | Flucelvax, Fluad |
| Paratek Pharmaceuticals, INC. | $17.36 | 2024 | Nuzyra |
| Nalu Medical, INC. | $16.31 | 2025 | Nalu Neurostimulation System |
| Allergan, INC. | $14.39 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adolph Nava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.